Cyramza
(Ramucirumab)Phase 3Monoclonal antibody
Eli LillyRamucirumab is used to treat certain types of advanced cancers, including stomach cancer, lung cancer, and colorectal cancer, by blocking a protein that helps tumors grow and spread.[1] Cyramza is currently being investigated across 18 indications[3], with its most advanced program in Phase 3.[1]
Cyramza is one of 296 small molecule programs targeting Stomach Neoplasm. It is currently in Phase 3.
18
Indications
138
Total Trials
41
Active Trials
295
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 18 indications
Competition
Competitive Landscape
414 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Cyramza
Eli LillyPhase 3
Albumin-Bound Paclitaxel
Bristol-Myers SquibbPhase 3
KN046
JJiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3
Divarasib
RochePhase 3
Remeron
OOrganon and Co
Preclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
PD-1 Inhibitors
BBioNTech US Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer16 trials
Show 13 more trials
Gastric Cancer10 trials
Show 7 more trials
A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06564298·39 enrolled
Gastroesophageal Junction Cancer6 trials
Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients
Active, not recruiting·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT03760822·112 enrolled
Show 3 more trials
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
Recruiting·—·Phase 2·NCT04660760·116 enrolled
Gastroesophageal Junction Adenocarcinoma6 trials
Show 3 more trials
Esophageal Cancer5 trials
66 more indications
Gastric Adenocarcinoma5 trials
Show 2 more trials
Adenocarcinoma4 trials
Lung Cancer4 trials
Hepatocellular Carcinoma3 trials
Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 1·NCT05856864·30 enrolled
Esophageal Adenocarcinoma3 trials
Advanced Cancer3 trials
Breast Cancer3 trials
Advanced Solid Tumors2 trials
Immune2 trials
Solid Tumors2 trials
Pembrolizumab2 trials
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
Recruiting·—·Phase 2·NCT04332367·59 enrolled
Liver Cancer2 trials
Tics2 trials
Recurrent Lung Non-Small Cell Carcinoma2 trials
Gastroesophageal Adenocarcinoma2 trials
Pancreatic Cancer1 trial
Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer
Completed·—·Phase 2·NCT02581215·84 enrolled
Renal Cancer1 trial
GastroEsophageal Junction (GEJ) Cancer1 trial
Transitional Cell Carcinoma1 trial
Locally Advanced1 trial
Biliary Cancer1 trial
Peritoneal Metastases1 trial
Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases
Recruiting·—·Phase 1·NCT06675136·30 enrolled
Synovial Sarcoma1 trial
Renal Cell Carcinoma1 trial
PD-L1 Positive1 trial
Gastrointestinal1 trial
Combination Therapy1 trial
Nivolumab1 trial
Gemcitabine1 trial
Pancreatic Adenocarcinoma1 trial
Refractory Solid Tumors1 trial
Glioblastoma Multiforme1 trial
Advanced NSCLC1 trial
Advanced Cancers1 trial
Stomach Cancer1 trial
Advanced Refractory Solid Tumors1 trial
Carcinoid Tumor1 trial
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Completed·—·Phase 2·NCT02795858·43 enrolled
Metastatic NSCLC1 trial
Fluorouracil1 trial
Patients With Solid Tumors1 trial
Gastric1 trial
FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)
Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2/3·NCT02661971·180 enrolled
Paclitaxel1 trial
Urothelial Cancer1 trial
Patients With Advanced Solid Tumors1 trial
Mesothelioma1 trial
Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
Terminated·—·Phase 2·NCT03502746·34 enrolled
Non-Small Cell Lung Carcinoma1 trial
Advanced or Metastatic Non-small Cell Lung Cancer1 trial
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma1 trial
Metastatic Small Intestinal Adenocarcinoma1 trial
Metastatic Non Small Cell Lung Cancer1 trial
Non-Squamous Non-Small Cell Lung Cancer1 trial
Lung1 trial
HER2-Negative1 trial
Metastatic Esophageal Adenocarcinoma1 trial
Head and Neck Squamous Cell Carcinoma1 trial
Neoplasms1 trial
Advanced or Metastatic Solid Tumor1 trial
Solid Tumor1 trial
Biliary Tract Cancer1 trial
Advanced Gastric or EGJ Cancer1 trial
Ramucirumab Plus Irinotecan / Leucovorin / 5-FU Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed One Prior Line of Palliative Chemotherapy - The Phase II/III RAMIRIS Study
Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Preclinical·NCT03081143·429 enrolled
Regulatory
FDA Approval Timeline[4]
Apr 21, 2014
CYRAMZA
BLA BLA125477
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ramucirumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]